Joseph Cappello - 12 May 2025 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Pharmaceutical Development
Signature
/s/ Sean Ryder, Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
12 May 2025
Net transactions value
-$13,832
Form type
4
Filing time
13 May 2025, 17:05:36 UTC
Previous filing
17 Apr 2025
Next filing
11 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cappello Joseph VP, Pharmaceutical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE /s/ Sean Ryder, Attorney-in-Fact 13 May 2025 0001939198

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Sale $13,832 -4,737 -8.3% $2.92 52,266 12 May 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.